10.11.2005 – 08:06

Intercell AG

euro adhoc: Intercell AG
other
Patent for Intercell’s proprietary Antigen Identification Program granted

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.

10.11.2005

Intercell AG today announced that the European Patent Office has
granted a European Patent 1355930 entitled "A method for
identification, isolation and production of antigens to a specific
pathogen". The patent protects the company’s proprietary Antigen
Identification Program, which uses antibodies from humans previously
exposed to the pathogen for selection of vaccine antigens and targets
for antibody therapies from genomic expression libraries of
bacterial, viral and fungal pathogens with high medical importance.
The unique strategic strength of the program is to employ the human
immune system as a comprehensive discovery machine to identify
protective antigens.

The Antigen Identification Program has already been used very
successfully to identify new vaccine candidates for own development
or development through strategic partnerships with key vaccine
players like Merck&Co., Inc., and sanofi pasteur.

"It is one of our strategic focuses to protect and strengthen our key
products and technologies by means of aggressive patent filing and
prosecution", states Alexander von Gabain, Chief Scientific Officer
of Intercell. "We are pleased about the issuance of this patent which
protects our Antigen Identification Technology AIP®. This enables a
successful further discovery of both further important vaccine
candidates and antibody therapies in the field of infectious
diseases."

About Intercell  Intercell AG is a fast growing biotechnology company
with a clear strategy and focus on the design and development of
novel vaccines for prevention and treatment of infectious diseases
with substantial unaddressed medical need. The Company’s unique
position is based on the combination of antigens and immunizers
(adjuvants) derived from its proprietary technology platforms and its
in-house GMP manufacturing facilities. Intercell’s technology has
been endorsed by collaborative agreements with a number of global
pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc.,
SciGen Ltd. and the Statens Serum Institut. The Company has a broad
development pipeline with a vaccine for Japanese Encephalitis
undergoing Phase III clinical trials, a vaccine for Hepatitis C in
Phase II trials, and five products focused on infectious diseases in
the pre-clinical phase. Intercell is listed on the Vienna stock
exchange under the symbol "ICLL".

This communication expressly or implicitly contains certain
forward-looking statements concerning Intercell AG and its business.
Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Intercell AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Intercell AG is providing this communication as of this date and does
not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

end of announcement                               euro adhoc 10.11.2005 07:30:00

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market